請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/80715完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 王尙麟(Shang-Lin Wang) | |
| dc.contributor.author | Chih-Ho Lee | en |
| dc.contributor.author | 李致和 | zh_TW |
| dc.date.accessioned | 2022-11-24T03:13:51Z | - |
| dc.date.available | 2021-11-04 | |
| dc.date.available | 2022-11-24T03:13:51Z | - |
| dc.date.copyright | 2021-11-04 | |
| dc.date.issued | 2021 | |
| dc.date.submitted | 2021-10-25 | |
| dc.identifier.citation | 1. Williams J, Phillips C, Byrd HM. Factors which influence owners when deciding to use chemotherapy in terminally ill pets. Animals 2017;7:18. 2. Thornton LA, Cave N, Bridges JP, Stell AJ. Owner perceptions of their cat’s quality of life when treated with a modified University of Wisconsin–Madison protocol for lymphoma. Journal of Feline Medicine and Surgery 2017;20:356-361. 3. Giuffrida MA, Brown DC, Ellenberg SS, Farrar JT. Development and psychometric testing of the Canine Owner-Reported Quality of Life questionnaire, an instrument designed to measure quality of life in dogs with cancer. Journal of the American Veterinary Medical Association 2018;252:1073-1083. 4. Johannes CM, Musser ML. Anorexia and the Cancer Patient. Veterinary Clinics of North America: Small Animal Practice 2019;49:837-854. 5. Mondello P, Lacquaniti A, Mondello S, Bolignano D, Pitini V, Aloisi C, Buemi M. Emerging markers of cachexia predict survival in cancer patients. BMC Cancer 2014;14:828. 6. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N,Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. The Lancet Oncology 2011;12:489-495. 7. Bennani-Baiti N, Walsh D. What is cancer anorexia-cachexia syndrome? A historical perspective. Journal of the Royal College of Physicians of Edinburgh 2009;39:257-262. 8. Sogame N, Risbon R, Burgess KE. Intestinal lymphoma in dogs: 84 cases (1997–2012). Journal of the American Veterinary Medical Association 2018;252:440-447. 9. Couto KM, Moore PF, Zwingenberger AL, Willcox JL, Skorupski KA. Clinical characteristics and outcome in dogs with small cell T-cell intestinal lymphoma. Veterinary and Comparative Oncology 2018;16:337-343. 10. Baez JL, Michel KE, Sorenmo K, Shofer, FS. A prospective investigation of the prevalence and prognostic significance of weight loss and changes in body condition in feline cancer patients. Journal of Feline Medicine and Surgery 2007;9:411-417. 11. Chapman PS. Regurgitation and vomiting. Small Animal Critical Care Medicine: Elsevier, 2015;634-638. 12. Vail DM. Supporting the Veterinary Cancer Patient on Chemotherapy: Neutropenia and Gastrointestinal Toxicity. Topics in Companion Animal Medicine 2009;24:122-129. 13. Withers SS, Kass PH, Rodriguez CO, Skorupski KA, O’Brien D, Guerrero TA, Sein KD, Rebhun RB. Fasting Reduces the Incidence of Delayed-Type Vomiting Associated with Doxorubicin Treatment in Dogs with Lymphoma. Translational Oncology 2014;7:377-383. 14. Cao J, Ouyang Q, Wang S, Ragaz J, Wang X, Teng Y, Wang B, Wang Z, Zhang J, Wang L, Wu J, Shao Z, Hu X. Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial. Investigational New Drugs 2020;38:507-514. 15. Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M. NCCN Guidelines Insights: Antiemesis, Version 2.2017. Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw 2017;15:883-893. 16. Davis MP, Khawam E, Pozuelo L, Lagman R. Management of symptons associated with advanced cancer: olanzapine and mirtazapine. Expert Review of Anticancer Therapy 2002;2:365-376. 17. Alam A, Voronovich Z, Carley JA. A review of therapeutic uses of mirtazapine in psychiatric and medical conditions. Prim Care Companion CNS Disord 2013;15:PCC.13r01525. 18. Kast RE, Foley KF. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. European Journal of Cancer Care 2007;16:351-354. 19. Riechelmann RP, Burman D, Tannock IF, Rodin G, Zimmermann C. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. American Journal of Hospice and Palliative Medicine® 2010;27:106-110. 20. Quimby JM, Gusrafson DL, Samber BJ, Lunn KF. Studies on the pharmacokinetics and pharmacodynamics of mirtazapine in healthy young cats. Journal of Veterinary Pharmacology and Therapeutics 2011;34:388-396. 21. Quimby JM, Lunn KF. Mirtazapine as an appetite stimulant and anti-emetic in cats with chronic kidney disease: A masked placebo-controlled crossover clinical trial. The Veterinary Journal 2013;197:651-655. 22. Agnew W, Korman R. Pharmacological appetite stimulation:Rational choices in the inappetent cat. Journal of Feline Medicine and Surgery 2014;16:749-756. 23. Ferguson LE, McLean MK, Bates JA, Quimby JM. Mirtazapine toxicity in cats: retrospective study of 84 cases (2006–2011). Journal of Feline Medicine and Surgery 2016;18:868-874. 24. Poole M, Quimby JM, Hu T, Labelle D, Buhles W. A double-blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss. Journal of Veterinary Pharmacology and Therapeutics 2019;42:179-188. 25. Hesketh PJ, Kris MG, Basch E, Bohlke K,Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH. Antiemetics: ASCO Guideline Update. Journal of Clinical Oncology 2020;38:2782-2797. 26. Paw Cho Sing E, Robinson PD, Flank J, Holdsworth M, Thackray J, Freedman J, Gibson P, Orsey AD, Patel P, Phillips R, Portwine C, Raybin JL, Cabral S, Sung L, DupuisLL. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. Pediatric Blood Cancer 2019;66:e27646. 27. Kenward H, Pelligand L, Savary-Bataille K, Elliott J. Nausea: Current knowledge of mechanisms, measurement and clinical impact. The Veterinary Journal 2015;203:36-43. 28. Kenward H, Elliott J, Lee T, Pelligand L. Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. BMC Veterinary Research 2017;13:244. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/80715 | - |
| dc.description.abstract | 米氮平 (Mirtazapine) 在人類醫學中已證實能預防高致吐性化學治療所造成的嘔吐與噁心感。然而，在獸醫領域未曾有研究探討米氮平在動物是否也有類似的治療效果。本篇研究的目的方為兩個方向：一、回溯性探討米氮平在接受化學治療貓隻的止吐與食慾促進效果；二、以隨機安慰劑對照單盲前瞻性臨床實驗評估米氮平在化療貓隻做為止吐劑與食慾促進劑的治療效果。回溯性研究納入90隻貓進入研究分組。其中，接受米氮平治療的組別其四周體重下降量顯著低於未接受米氮平治療的組別(p = 0.024)。而以不同的化學治療藥物的分組比較中，米氮平能顯著降低接受蒽環類(Anthracyclines)藥物治療貓隻之四周體重減少幅度(p = 0.007)。在經歷組別交換(crossover)的貓隻中，有19隻貓的體重資料能以治療期間與化療藥物為條件對照比較。單一個體在相同治療期間與使用相同化療藥物條件下，使用米氮平期間的體重變化量亦顯著小於不使用米氮平期間的體重變化量。前瞻性實驗共納入6隻貓，並隨機分派使用米氮平(1.88毫克/貓)或安慰劑，以每48小時經口投藥的方式進行兩周的實驗觀察。實驗的貓隻會經歷四天的停藥期後交換組別至相對試驗藥物組別以相同方式完成實驗。試驗期間主人需記錄貓隻精神、食慾、每日嘔吐次數與下痢情況，並量測每周體重。與給予安慰劑期間的體重變化量相比，接受化學治療的貓隻在使用兩週米氮平治療時，其體重下降程度顯著較少(p = 0.043)。但給予米氮平對於化療貓隻之精神、食慾、嘔吐與下痢等臨床症狀並無顯著的改善。基於以上研究結果，我們認為雖然未能直接於臨床上觀察到米氮平止吐與食慾促進的效果，但其能作為接受化學治療貓隻的輔助用藥，降低化療過程中體重下降的程度。對於使用米氮平於化療貓隻止吐劑與食慾促進劑的效果仍需更多進一步的研究評估。 | zh_TW |
| dc.description.provenance | Made available in DSpace on 2022-11-24T03:13:51Z (GMT). No. of bitstreams: 1 U0001-1710202102411400.pdf: 1999992 bytes, checksum: 493e44f7d30914c561c3b0cea8f9beb0 (MD5) Previous issue date: 2021 | en |
| dc.description.tableofcontents | 中文摘要 ii Abstract iii Table of Contents iv List of Figures vi List of Tables vii List of Abbreviations viii Chapter 1. Introduction 1 1.1 Inappetence in veterinary cancer patients 1 1.2 Cancer-related anorexia/cachexia syndrome 2 1.2.1 Chemotherapy-induced nausea and vomiting (CINV) 3 1.2.2 CINV in veterinary cancer patients 4 1.2.3 CINV in human cancer patients 5 1.3 Mirtazapine 5 1.3.1 The clinical application of mirtazapine in human medicine 5 1.3.2 Mirtazapine in veterinary medicine 6 Chapter 2. Aim of the thesis 8 Chapter 3. Material and Methods 9 3.1 Retrospective study 9 3.1.1 Animals 9 3.1.2 Medical records review 9 3.1.3 Statistical analysis 11 3.2 Prospective study 14 3.2.1 Animals 14 3.2.2 Study design 15 3.2.3 Statistical analysis 19 Chapter 4. Results 20 4.1 Retrospective study 20 4.1.1 Animals 20 4.1.2 Weight change over time in the mirtazapine group and the non-mirtazapine group 23 4.1.3 Four-week weight change in the mirtazapine-receiving and non-mirtazapine-receiving cats categorized by different chemotherapy protocols 28 4.1.4 Comparison of weight change over time in the mirtazapine and the non-mirtazapine phase paired by time point and cytotoxic drug administered in single individual 32 4.2 Prospective study 35 4.2.1 Animals 35 4.2.2 Weight change over time between mirtazapine phase and placebo phase 38 4.2.3 Clinical score between mirtazapine phase and placebo phase 43 Chapter 5. Discussion 46 Chapter 6. Conclusion 52 Reference 53 | |
| dc.language.iso | en | |
| dc.subject | 米氮平 | zh_TW |
| dc.subject | 貓 | zh_TW |
| dc.subject | 厭食 | zh_TW |
| dc.subject | 嘔吐 | zh_TW |
| dc.subject | 化學治療 | zh_TW |
| dc.subject | anorexia | en |
| dc.subject | cat | en |
| dc.subject | mirtazapine | en |
| dc.subject | chemotherapy | en |
| dc.subject | vomit | en |
| dc.title | 評估米氮平於化療貓隻作為止吐劑與食慾促進劑的治療效果 | zh_TW |
| dc.title | Evaluation of mirtazapine as an antiemetic and appetite-stimulating agent in cats receiving chemotherapy | en |
| dc.date.schoolyear | 109-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 李繼忠(Hsin-Tsai Liu),劉以立(Chih-Yang Tseng),王儷蒨,廖泰慶 | |
| dc.subject.keyword | 貓,厭食,嘔吐,化學治療,米氮平, | zh_TW |
| dc.subject.keyword | cat,anorexia,vomit,chemotherapy,mirtazapine, | en |
| dc.relation.page | 55 | |
| dc.identifier.doi | 10.6342/NTU202103790 | |
| dc.rights.note | 同意授權(限校園內公開) | |
| dc.date.accepted | 2021-10-26 | |
| dc.contributor.author-college | 獸醫專業學院 | zh_TW |
| dc.contributor.author-dept | 臨床動物醫學研究所 | zh_TW |
| 顯示於系所單位： | 臨床動物醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-1710202102411400.pdf 授權僅限NTU校內IP使用（校園外請利用VPN校外連線服務） | 1.95 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。